BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary
flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome
patients at week 12 compared to the baseline visit.